Description
Ligandrol is an orally active nonsteroidal SARM developed by Ligand Pharmaceuticals that has completed Phase I clinical trials which involved multiple ascending doses in healthy volunteers.According to the National Institute of Health’s U.S. National Library of Medicine, in Phase I clinicaltrials “Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.” These clinical trials showed that humans could safely tolerate up to 22mg/day of this compound for 14 consecutive days; this compound contributed to increases in lean body mass, decreases in fat mass,increases in strength, as well as an increases in senses of well-being.
Ligandrol also appears to decrease bone turnover rate, which appeals to those with osteoporosis. Based on these findings, it appears that LGD4033 is an excellent SARM for bulking, cutting, recomposition, or strength-gain phases.
Application
LGD-4033 is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Reviews
There are no reviews yet.